Palmitoylethanolamide Is a Disease-Modifying Agent in Peripheral Neuropathy: Pain Relief and Neuroprotection Share a PPAR-Alpha-Mediated Mechanism

Figure 8

CD86 positive cells evaluation in sciatic nerve. 14 days after CCI, 5 μm sections of the formalin-fixed distal part of the sciatic nerve underwent immunohistochemical staining for CD86. Effect of PEA repeated treatments (30 mg kg⁻¹ s.c. daily) was evaluated in (a) PPAR-𝛼^+/+ and in (b) PPAR-𝛼^−/− mice, and quantitative analysis was performed evaluating 5 animals for each group. ^∗𝑃<0.05 was considered as significantly different from sham, vehicle-treated mice. ^∘𝑃<0.05 was considered as significantly different from CCI, vehicle-treated mice.

(a)

(b)